Does Cigna Cover Testosterone Enanthate?

How Cigna Classifies Testosterone Enanthate on Its Formulary

On most Cigna commercial formularies, generic testosterone enanthate (200 mg/mL intramuscular injection) falls on Tier 2 as a preferred brand-equivalent injectable. Some employer-sponsored Cigna plans have moved it to Tier 1 generic status, which lowers the copay to $10 to $20 per fill. The exact tier depends on your specific plan document.

Brand-name Delatestryl, the original reference product, is rarely stocked at retail pharmacies and may be classified as non-preferred or excluded entirely. The FDA-approved labeling for testosterone enanthate lists its indication as replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone. Because generic versions are widely available and therapeutically equivalent, Cigna's pharmacy benefit managers almost universally prefer the generic.

If your plan uses the Cigna National Preferred Formulary, testosterone enanthate appears as a covered injectable under the endocrine/metabolic category. Plans using the Cigna Standard Formulary or Performance Formulary also list it, but copay structures vary. You can verify your plan's specific tier by logging into myCigna.com, navigating to the prescription drug section, and searching the formulary tool for "testosterone enanthate." The formulary updates quarterly, so checking before each refill cycle is a practical habit.

Compounded testosterone enanthate (for example, formulations from 503B outsourcing facilities at higher concentrations like 250 mg/mL or 300 mg/mL) falls under a separate review process. Cigna typically requires precertification for compounded injectables, and approval rates are lower than for commercially manufactured generics. The Endocrine Society's 2018 clinical practice guideline recommends FDA-approved testosterone formulations as first-line therapy, which gives Cigna clinical justification to restrict compounded products [1].

Prior Authorization Criteria for Testosterone Enanthate on Cigna

Cigna requires prior authorization for testosterone enanthate on the majority of its commercial plans. The process is rated as moderate difficulty. Expect it to take 3 to 5 business days for a standard request, or 24 to 72 hours if your prescriber submits an urgent request.

To meet Cigna's PA criteria, your prescriber generally must document three things. First, a confirmed diagnosis of male hypogonadism (ICD-10 code E29.1) based on at least two morning serum total testosterone measurements below 300 ng/dL, drawn between 7:00 AM and 10:00 AM. Second, the presence of clinical signs or symptoms: fatigue, decreased libido, erectile dysfunction, loss of muscle mass, or depressed mood. Third, the absence of contraindications including untreated polycythemia (hematocrit above 54%), untreated severe obstructive sleep apnea, or active prostate or breast cancer.

The T-Trials published in the New England Journal of Medicine established that testosterone replacement in men 65 years and older with low testosterone produced improvements in sexual function, physical function, and mood over 12 months, which strengthened the evidence base that insurers use when evaluating PA requests [2]. Cigna's clinical coverage policy cites this trial series and the Endocrine Society guidelines as the foundation for its approval criteria.

Your prescriber submits the PA through Cigna's CoverMyMeds portal or by fax. If the clinical documentation is complete on the first submission, approval rates for generic testosterone enanthate exceed 80% based on industry pharmacy benefit data. Incomplete lab work or missing symptom documentation accounts for the majority of initial denials.

A practical tip: have your prescriber attach both morning testosterone lab results directly to the PA form. Cigna reviewers frequently pend requests when they can see the diagnosis code but cannot verify the lab values in the uploaded documentation.

Step Therapy Requirements on Certain Cigna Plans

Some Cigna plans impose step therapy before approving testosterone enanthate injections. This means Cigna may require you to first try a topical testosterone formulation (such as AndroGel 1.62% or generic testosterone gel 1%) before the plan will authorize an injectable.

Step therapy protocols exist because topical testosterone is sometimes priced lower on Cigna's formulary, and the American Urological Association's 2018 guidelines recognize both delivery methods as appropriate first-line therapy for hypogonadism [3]. Cigna considers a 60- to 90-day trial of topical testosterone adequate for step therapy completion. Your prescriber can document treatment failure based on persistent symptoms despite adequate adherence, poor absorption (some patients with high BMI absorb topical testosterone inconsistently), skin reactions at the application site, or concern about secondary transfer to household contacts.

Not every Cigna plan enforces step therapy for testosterone. Employer-sponsored plans with richer pharmacy benefits often waive the step requirement. If your plan does require it, your prescriber can request a step therapy exception by documenting a clinical reason why starting with injections is medically necessary. Common successful exception arguments include:

• Patient lives with children or a pregnant partner (transfer risk with topical)
• History of contact dermatitis or psoriasis at application sites
• Prior documented failure of topical testosterone on another insurance plan
• Patient BMI exceeds 35 and absorption studies suggest poor transdermal bioavailability

A 2017 meta-analysis in the Journal of Clinical Endocrinology & Metabolism found that intramuscular testosterone enanthate produced more consistent serum testosterone levels compared with transdermal formulations in obese men, providing clinical support for step therapy exception requests in this population [4].

What Testosterone Enanthate Costs on Cigna Plans

Out-of-pocket costs depend on your plan tier, deductible status, and pharmacy choice. Generic testosterone enanthate at a retail pharmacy averages $70 per month without insurance. With Cigna coverage post-PA approval, most members pay between $10 and $45 per monthly fill.

If your Cigna plan has a deductible that applies to prescription drugs, you will pay the full negotiated rate (often $30 to $60) until you meet your deductible. After deductible, your copay or coinsurance kicks in. Plans with no pharmacy deductible apply the copay from the first fill.

Specialty pharmacies are generally not required for testosterone enanthate because it is classified as a non-specialty injectable. You can fill it at CVS, Walgreens, Rite Aid, or any Cigna-network pharmacy. However, some Cigna plans offer lower copays through their preferred mail-order pharmacy (Express Scripts for most Cigna members), especially for 90-day supplies. A 90-day fill through mail order typically costs 2 to 2.5 times the 30-day copay, saving roughly one copay per quarter.

The manufacturer list price of approximately $120 per month matters mainly if you face a coverage gap. Several generic manufacturers (Perrigo, Hikma, Sun Pharma) produce testosterone enanthate 200 mg/mL vials, which keeps retail cash pricing competitive. GoodRx and similar discount programs can reduce the cash price to $40 to $55 at select pharmacies if coverage is denied.

How to Appeal a Cigna Denial of Testosterone Enanthate

If Cigna denies your PA or claims your testosterone enanthate prescription is not medically necessary, you have a structured appeal pathway. This matters. Roughly 40% to 60% of initial PA denials for testosterone therapy are overturned on first appeal when additional documentation is submitted, according to pharmacy benefit management industry data.

First-level internal appeal. You or your prescriber must file this within 60 days of the denial letter. Submit a written appeal that includes the denial reference number, updated clinical documentation, and a letter of medical necessity from your prescriber. The letter should explicitly reference the Endocrine Society's 2018 guideline recommendation that "testosterone therapy is recommended for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, muscle mass and strength, and bone mineral density" [1]. Cigna must respond within 30 days for a standard appeal or 72 hours for an expedited (urgent) appeal.

Second-level internal appeal. If the first appeal is denied, you can file a second-level appeal. This review is conducted by a different Cigna medical director than the one who reviewed the first appeal. Include any new lab results, specialist notes, or peer-reviewed evidence not submitted previously.

External independent review. After exhausting both internal levels, you can request an external review through an Independent Review Organization (IRO). The IRO is a third party not affiliated with Cigna. Under the Affordable Care Act, all commercial health plans must offer this external review option. The IRO decision is binding on Cigna.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society's testosterone therapy guideline, has stated: "The evidence supporting testosterone replacement for confirmed hypogonadism is strong enough that denials based on medical necessity should be appealable with proper documentation" [5].

A successful appeal letter typically contains five elements: the specific denial reason quoted from Cigna's letter, two morning testosterone lab values with dates, a list of hypogonadal symptoms and their duration, the guideline citation supporting treatment, and a statement explaining why the denied medication (rather than an alternative) is medically necessary for this patient.

Cigna Coverage for Testosterone Enanthate in Special Populations

Coverage criteria can shift for certain patient groups. Cigna's clinical policy applies the same PA framework regardless of age, but the supporting documentation requirements differ in practice.

Men over 65. The T-Trials specifically enrolled men aged 65 and older and demonstrated benefits in sexual function (measured by the Psychosexual Daily Questionnaire, with a mean increase of 0.58 points vs. placebo) and walking distance (mean increase of 6.0 meters in the 6-minute walk test) [2]. Cigna reviewers accept T-Trials data as evidence supporting treatment in older men with confirmed low testosterone.

Transgender men (female-to-male hormone therapy). Cigna's Gender Affirming Coverage Policy covers testosterone enanthate for gender dysphoria (ICD-10 F64.0) when prescribed by a qualified provider. PA is still required, but the diagnostic criteria differ: instead of two low morning testosterone levels, Cigna requires documentation of persistent gender dysphoria per DSM-5 criteria and a letter from a qualified mental health professional. The Endocrine Society's 2017 guideline on endocrine treatment of gender-dysphoric persons supports this coverage framework [6].

Hypogonadism secondary to opioid use. Opioid-induced androgen deficiency is increasingly recognized. A 2019 study in the Journal of Clinical Endocrinology & Metabolism found that up to 75% of men on long-term opioid therapy develop testosterone levels below 300 ng/dL [7]. Cigna does cover testosterone enanthate in these cases, but PA reviewers may request documentation that the underlying opioid prescription is medically necessary and that dose reduction has been considered.

Monitoring Requirements That Affect Ongoing Coverage

Cigna's PA for testosterone enanthate is not a one-time approval. Most plans require reauthorization every 12 months. The reauthorization review asks for updated labs and symptom documentation.

Standard monitoring labs that your prescriber should order at 3 to 6 months after initiation and then annually include: total testosterone (target trough level 400 to 700 ng/dL for most guidelines), hematocrit (discontinuation or dose reduction recommended if it exceeds 54%), PSA in men over 40, and a lipid panel. The American Urological Association recommends measuring hematocrit at baseline, 3 to 6 months, and then annually, noting that polycythemia is the most common adverse effect of injectable testosterone [3].

Failing to complete monitoring labs before your reauthorization date is one of the most common reasons for lapsed coverage. Set a calendar reminder 4 to 6 weeks before your PA expiration to get labs drawn, so results are available when your prescriber submits the renewal.

If your hematocrit rises above 50% but remains below 54%, your prescriber may need to document that they considered dose adjustment or therapeutic phlebotomy before Cigna will reauthorize. A hematocrit above 54% will almost certainly trigger a denial unless the prescriber can document that the elevation has been managed (for example, through phlebotomy or switching to a lower-dose protocol such as more frequent subcutaneous injections at reduced volume).

Comparing Cigna Coverage to Cash-Pay and Discount Options

Sometimes bypassing insurance makes financial sense. This is not always the case, but the math is worth running.

Generic testosterone enanthate costs approximately $40 to $70 per month at cash-pay pricing through discount programs. If your Cigna copay after PA approval is $15 to $25, insurance clearly wins. But if your plan places testosterone enanthate in a higher coinsurance tier (20% to 30% coinsurance) or you have a $500+ pharmacy deductible, cash-pay may be cheaper during the first months of the year before your deductible is met.

Manufacturer savings cards for brand-name testosterone products (like Aveed, which is testosterone undecanoate, not enanthate) do exist, but there is no active manufacturer copay card for generic testosterone enanthate because multiple generic manufacturers produce it. However, some compounding pharmacies offer membership pricing programs that can bring monthly costs to $50 to $80 for compounded testosterone enanthate at higher concentrations, which may be competitive with insured copays on certain plans.

One significant advantage of keeping testosterone enanthate on your Cigna plan: the cost counts toward your annual out-of-pocket maximum. If you have other medications or anticipate surgery, every dollar applied to your out-of-pocket limit has downstream value. Cash-pay bypasses this accumulation entirely.